Cargando…

GlycA Levels during the Earliest Stages of Rheumatoid Arthritis: Potential Use as a Biomarker of Subclinical Cardiovascular Disease

This study aimed at evaluating the clinical relevance of glycoprotein profiles during the earliest phases of rheumatoid arthritis (RA) as biomarkers of cardiovascular (CV) risk and treatment response. Then, GlycA and GlycB serum levels were measured using 1H-nuclear magnetic resonance in 82 early RA...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodríguez-Carrio, Javier, Alperi-López, Mercedes, López, Patricia, Pérez-Álvarez, Ángel I., Gil-Serret, Miriam, Amigó, Núria, Ulloa, Catalina, Benavente, Lorena, Ballina-García, Francisco J., Suárez, Ana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7463667/
https://www.ncbi.nlm.nih.gov/pubmed/32752190
http://dx.doi.org/10.3390/jcm9082472
_version_ 1783577185558200320
author Rodríguez-Carrio, Javier
Alperi-López, Mercedes
López, Patricia
Pérez-Álvarez, Ángel I.
Gil-Serret, Miriam
Amigó, Núria
Ulloa, Catalina
Benavente, Lorena
Ballina-García, Francisco J.
Suárez, Ana
author_facet Rodríguez-Carrio, Javier
Alperi-López, Mercedes
López, Patricia
Pérez-Álvarez, Ángel I.
Gil-Serret, Miriam
Amigó, Núria
Ulloa, Catalina
Benavente, Lorena
Ballina-García, Francisco J.
Suárez, Ana
author_sort Rodríguez-Carrio, Javier
collection PubMed
description This study aimed at evaluating the clinical relevance of glycoprotein profiles during the earliest phases of rheumatoid arthritis (RA) as biomarkers of cardiovascular (CV) risk and treatment response. Then, GlycA and GlycB serum levels were measured using 1H-nuclear magnetic resonance in 82 early RA patients, 14 clinically-suspect arthralgia (CSA), and 28 controls. Serum glycosyltransferase activity was assessed by a colorimetric assay. Subclinical CV disease was assessed by Doppler-ultrasound. We found that GlycA and GlycB serum levels were increased in RA (both p < 0.001), but not in CSA, independently of cardiometabolic risk factors. Increased serum glycosyltransferase activity paralleled GlycA (r = 0.405, p < 0.001) and GlycB levels (r = 0.327, p = 0.005) in RA. GlycA, but not GlycB, was associated with atherosclerosis occurrence (p = 0.012) and severity (p = 0.001). Adding GlycA to the mSCORE improved the identification of patients with atherosclerosis over mSCORE alone, increasing sensitivity (29.7 vs. 68.0%) and accuracy (55.8 vs. 76.6%) and allowing reclassification into more appropriate risk categories. GlycA-reclassification identified patients with impaired lipoprotein metabolism. Finally, baseline GlycA levels predicted poor clinical response upon anti-rheumatic treatment at 6 and 12 months in univariate and multivariate analysis. In sum, increased GlycA levels during the earliest stage of RA can be considered a powerful biomarker for CV risk stratification and treatment response.
format Online
Article
Text
id pubmed-7463667
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74636672020-09-02 GlycA Levels during the Earliest Stages of Rheumatoid Arthritis: Potential Use as a Biomarker of Subclinical Cardiovascular Disease Rodríguez-Carrio, Javier Alperi-López, Mercedes López, Patricia Pérez-Álvarez, Ángel I. Gil-Serret, Miriam Amigó, Núria Ulloa, Catalina Benavente, Lorena Ballina-García, Francisco J. Suárez, Ana J Clin Med Article This study aimed at evaluating the clinical relevance of glycoprotein profiles during the earliest phases of rheumatoid arthritis (RA) as biomarkers of cardiovascular (CV) risk and treatment response. Then, GlycA and GlycB serum levels were measured using 1H-nuclear magnetic resonance in 82 early RA patients, 14 clinically-suspect arthralgia (CSA), and 28 controls. Serum glycosyltransferase activity was assessed by a colorimetric assay. Subclinical CV disease was assessed by Doppler-ultrasound. We found that GlycA and GlycB serum levels were increased in RA (both p < 0.001), but not in CSA, independently of cardiometabolic risk factors. Increased serum glycosyltransferase activity paralleled GlycA (r = 0.405, p < 0.001) and GlycB levels (r = 0.327, p = 0.005) in RA. GlycA, but not GlycB, was associated with atherosclerosis occurrence (p = 0.012) and severity (p = 0.001). Adding GlycA to the mSCORE improved the identification of patients with atherosclerosis over mSCORE alone, increasing sensitivity (29.7 vs. 68.0%) and accuracy (55.8 vs. 76.6%) and allowing reclassification into more appropriate risk categories. GlycA-reclassification identified patients with impaired lipoprotein metabolism. Finally, baseline GlycA levels predicted poor clinical response upon anti-rheumatic treatment at 6 and 12 months in univariate and multivariate analysis. In sum, increased GlycA levels during the earliest stage of RA can be considered a powerful biomarker for CV risk stratification and treatment response. MDPI 2020-08-01 /pmc/articles/PMC7463667/ /pubmed/32752190 http://dx.doi.org/10.3390/jcm9082472 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Rodríguez-Carrio, Javier
Alperi-López, Mercedes
López, Patricia
Pérez-Álvarez, Ángel I.
Gil-Serret, Miriam
Amigó, Núria
Ulloa, Catalina
Benavente, Lorena
Ballina-García, Francisco J.
Suárez, Ana
GlycA Levels during the Earliest Stages of Rheumatoid Arthritis: Potential Use as a Biomarker of Subclinical Cardiovascular Disease
title GlycA Levels during the Earliest Stages of Rheumatoid Arthritis: Potential Use as a Biomarker of Subclinical Cardiovascular Disease
title_full GlycA Levels during the Earliest Stages of Rheumatoid Arthritis: Potential Use as a Biomarker of Subclinical Cardiovascular Disease
title_fullStr GlycA Levels during the Earliest Stages of Rheumatoid Arthritis: Potential Use as a Biomarker of Subclinical Cardiovascular Disease
title_full_unstemmed GlycA Levels during the Earliest Stages of Rheumatoid Arthritis: Potential Use as a Biomarker of Subclinical Cardiovascular Disease
title_short GlycA Levels during the Earliest Stages of Rheumatoid Arthritis: Potential Use as a Biomarker of Subclinical Cardiovascular Disease
title_sort glyca levels during the earliest stages of rheumatoid arthritis: potential use as a biomarker of subclinical cardiovascular disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7463667/
https://www.ncbi.nlm.nih.gov/pubmed/32752190
http://dx.doi.org/10.3390/jcm9082472
work_keys_str_mv AT rodriguezcarriojavier glycalevelsduringtheearlieststagesofrheumatoidarthritispotentialuseasabiomarkerofsubclinicalcardiovasculardisease
AT alperilopezmercedes glycalevelsduringtheearlieststagesofrheumatoidarthritispotentialuseasabiomarkerofsubclinicalcardiovasculardisease
AT lopezpatricia glycalevelsduringtheearlieststagesofrheumatoidarthritispotentialuseasabiomarkerofsubclinicalcardiovasculardisease
AT perezalvarezangeli glycalevelsduringtheearlieststagesofrheumatoidarthritispotentialuseasabiomarkerofsubclinicalcardiovasculardisease
AT gilserretmiriam glycalevelsduringtheearlieststagesofrheumatoidarthritispotentialuseasabiomarkerofsubclinicalcardiovasculardisease
AT amigonuria glycalevelsduringtheearlieststagesofrheumatoidarthritispotentialuseasabiomarkerofsubclinicalcardiovasculardisease
AT ulloacatalina glycalevelsduringtheearlieststagesofrheumatoidarthritispotentialuseasabiomarkerofsubclinicalcardiovasculardisease
AT benaventelorena glycalevelsduringtheearlieststagesofrheumatoidarthritispotentialuseasabiomarkerofsubclinicalcardiovasculardisease
AT ballinagarciafranciscoj glycalevelsduringtheearlieststagesofrheumatoidarthritispotentialuseasabiomarkerofsubclinicalcardiovasculardisease
AT suarezana glycalevelsduringtheearlieststagesofrheumatoidarthritispotentialuseasabiomarkerofsubclinicalcardiovasculardisease